Welcome to our dedicated page for PARKERVISION SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PARKERVISION's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PARKERVISION's regulatory disclosures and financial reporting.
ParkerVision, Inc. filed a prospectus supplement that updates its existing resale registration covering up to 16,638,353 shares of common stock issuable upon conversion of, and as interest paid in stock on, convertible promissory notes dated between May 10, 2022 and August 3, 2022 at a fixed conversion price of $0.13 per share.
The supplement incorporates a recent report describing new equity incentives for executives. The compensation committee granted performance-based stock options to the CEO for up to 8,000,000 shares and to the CFO for up to 500,000 shares, plus a time-based option for the CFO for up to 500,000 shares, all with a $0.24 exercise price. Vesting for the performance awards is tied to cumulative net cash from patent enforcement actions, with accelerated vesting if the company’s market capitalization reaches $1 billion for 20 consecutive trading days or upon a change in control. The CEO and CFO also received a 2.5% cost-of-living salary increase effective April 15, 2026.
ParkerVision, Inc. filed a prospectus supplement covering the resale by a selling stockholder of up to 1,578,946 shares of common stock, including 1,052,631 existing shares and 526,315 shares issuable upon exercise of warrants. The company will not receive proceeds from resales, but could receive up to $526,315 in gross proceeds if the warrants are exercised for cash, which it plans to use for general working capital, including litigation expenses.
The attached report also describes new equity awards for executives under the 2019 Long-Term Incentive Plan. The CEO received a performance-based option for up to 8,000,000 shares and the CFO received a performance-based option for up to 500,000 shares, both with a $0.24 exercise price, a five-year performance period with quarterly measurement dates, and ten-year terms, vesting based on cumulative net cash from patent enforcement actions. Vesting accelerates if market capitalization reaches $1 billion for 20 consecutive trading days or upon a change in control. The CFO also received a time-based option for up to 500,000 shares at $0.24, vesting over two years, and both executives received a 2.5% cost-of-living salary increase effective April 15, 2026.
ParkerVision, Inc. has a prospectus supplement covering the resale by existing stockholders of up to 13,342,953 shares of common stock, including shares previously issued in securities purchase agreements, shares underlying warrants, and shares issued as payment for services. The company will not receive any proceeds from stockholder resales, but could receive up to $2,833,756 in gross proceeds if the associated warrants are exercised for cash, which it plans to use for general working capital, including litigation expenses.
The filing also describes new equity incentives for executives. The CEO received a performance-based stock option for up to 8,000,000 shares and the CFO received a performance-based option for up to 500,000 shares, both with a $0.24 exercise price and a five-year performance period tied to cumulative net cash from patent enforcement actions. These options fully vest early if the company’s market capitalization reaches $1 billion for 20 consecutive trading days or upon a change in control. The CFO also received a time-based option for up to 500,000 shares at $0.24 per share, and both executives were granted a 2.5% cost-of-living base salary increase.
ParkerVision, Inc. filed a prospectus supplement covering the resale by existing holders of up to 5,871,584 shares of common stock; the company will not receive any proceeds from these sales. The supplement incorporates a new current report detailing significant equity incentives for senior management.
The compensation committee granted the CEO a performance-based stock option for up to 8,000,000 shares and the CFO a performance-based option for up to 500,000 shares, each with a five-year performance period, ten-year term, and an exercise price of $0.24 per share. Vesting depends on cumulative net cash received from patent enforcement actions and can accelerate if the company’s market capitalization reaches $1 billion for 20 consecutive trading days or upon a change in control. The CFO also received a time-based option for up to 500,000 shares vesting over two years, and both executives will receive a 2.5% cost-of-living salary increase effective April 15, 2026.
ParkerVision, Inc. filed a prospectus supplement tied to an existing resale registration covering up to 16,809,295 shares of common stock. These shares include stock issued in prior financings and services, as well as shares issuable upon conversion of earlier convertible notes and upon exercise of warrants held by Aspire Capital Fund LLC and Tailwinds Research Group LLC. The company will not receive proceeds from stockholder resales, but could receive up to $3,900,000 in gross proceeds if the Aspire and Tailwinds warrants are exercised for cash.
The attached current report describes new equity incentives for executives under the 2019 Long-Term Incentive Plan. The Compensation Committee granted a performance-based stock option for up to 8,000,000 shares to the CEO and up to 500,000 shares to the CFO, both with a five-year performance period and a ten-year term, at an exercise price of $0.24 per share. Vesting depends mainly on cumulative net cash from patent enforcement actions, with automatic acceleration if the company’s market capitalization reaches $1 billion for 20 consecutive trading days or upon a change in control. The CFO also received a time-based option for up to 500,000 shares and a 2.5% cost-of-living salary increase, matching a similar increase for the CEO.
ParkerVision, Inc. filed a prospectus supplement covering the resale of up to 18,014,164 shares of common stock by existing holders. These shares come from prior convertible notes, consulting share issuances, and a warrant granted for services. The company will not receive any proceeds from stockholder resales, but may receive up to $180,000 if a service-related warrant is exercised for cash, which would be used for working capital and general corporate purposes.
The attached current report also describes new equity compensation for executives. The CEO received a performance-based option for up to 8,000,000 shares and the CFO received performance-based options for up to 500,000 shares, all at an exercise price of $0.24 per share, with vesting tied to net cash from patent enforcement and certain market capitalization or change-of-control triggers. The CFO also received a separate time-based option for up to 500,000 shares and both executives were granted a 2.5% cost-of-living salary increase.
ParkerVision, Inc. files a prospectus supplement covering the resale by existing holders of up to 17,189,660 shares of common stock previously registered under earlier shelf and resale statements. The company will not receive proceeds from these stockholder resales, but may receive up to $700,000 from cash exercises of a 2016 warrant and up to $1,763,500 from stock sales or warrant exercises under its agreement with Aspire Capital, which it expects to use for patent enforcement and general corporate purposes.
The attached report also discloses new performance-based stock option grants under the 2019 plan: up to 8,000,000 shares for the CEO and 500,000 shares for the CFO, vesting over a five-year performance period tied to net cash from patent enforcement, with accelerated vesting if the company’s market capitalization reaches $1 billion for 20 consecutive trading days or upon a change in control. The CFO also receives a time-based option for up to 500,000 shares and both executives receive a 2.5% cost-of-living base salary increase.
ParkerVision, Inc. updates its resale prospectus covering up to 12,800,000 shares of common stock, which may be sold from time to time by existing selling stockholders. The company will not receive proceeds from these resales, but could receive up to $800,000 in gross proceeds if an associated warrant is exercised for cash, which it expects to use for patent enforcement actions and general working capital.
The company also approved new nonqualified stock option grants under its 2019 Long-Term Incentive Plan. The CEO received a performance-based option for up to 8,000,000 shares and the CFO a performance-based option for up to 500,000 shares, both with a five-year performance period and a ten-year term, at an exercise price of $0.24 per share. Vesting is tied to cumulative net cash from patent enforcement actions and may accelerate if market capitalization reaches $1 billion for twenty consecutive trading days or upon a change in control. The CFO also received a time-based option for up to 500,000 shares vesting over two years, and both executives will receive a 2.5% cost-of-living base salary increase effective April 15, 2026.
ParkerVision, Inc. reported new compensation awards for its top executives. On January 22, 2026, the board’s compensation committee granted performance-based stock options under the 2019 Long-Term Incentive Plan, including an option to purchase up to 8,000,000 shares for CEO Jeffrey Parker and an option to purchase up to 500,000 shares for CFO Cynthia French.
The options have a five-year performance period with quarterly measurement dates, a ten-year term, and an exercise price of $0.24 per share, based on the last sale price on the grant date. Vesting depends on cumulative net cash the company receives from its patent enforcement actions after specified fees and repayments.
These performance options fully vest automatically if the company’s market capitalization reaches at least $1 billion for 20 consecutive trading days or upon a change in control. The committee also granted the CFO a separate time-based option for up to 500,000 shares at $0.24 per share, vesting in four equal biannual installments over two years beginning July 22, 2026, and approved a 2.5% cost-of-living increase in the base salaries of the CEO and CFO effective April 15, 2026.
ParkerVision, Inc. filed a prospectus supplement that continues to permit the resale by existing shareholders of up to 9,387,500 shares of common stock. These shares include 2,843,750 shares already issued under prior securities purchase agreements, 6,343,750 shares issuable upon conversion or interest payments on convertible notes at a fixed conversion price of $0.16 per share, and 200,000 shares issuable upon exercise of options granted for services. The company will not receive proceeds from shareholder resales but could receive up to $42,620 if the options are exercised for cash.
The supplement also incorporates a new Form 8-K, which reports that on November 24, 2025 ParkerVision completed a separate registered offering and sale of 16,481,579 common shares to accredited investors for an aggregate purchase price of $3,461,132, using its shelf registration statement. No underwriters, placement agents, brokers, or finders were engaged, and no commissions or fees were paid.